Central Nervous System Drugs Market by Drug Classes (Analgesics, Anesthetics, Anti-Epileptics), Diseases (CNS Trauma, Infectious Diseases, Mental Health), Drug Type, Distribution Channel - Global Forecast 2024-2030

Central Nervous System Drugs Market by Drug Classes (Analgesics, Anesthetics, Anti-Epileptics), Diseases (CNS Trauma, Infectious Diseases, Mental Health), Drug Type, Distribution Channel - Global Forecast 2024-2030


The Central Nervous System Drugs Market size was estimated at USD 20.71 billion in 2023 and expected to reach USD 22.44 billion in 2024, at a CAGR 9.85% to reach USD 39.99 billion by 2030.Drugs for the Central nervous system (CNS) include sedatives, tranquilizers, and hypnotics for treating anxiety, panic, acute stress reactions, and sleep disorders. Central nervous system (CNS) drug companies have experienced extensive R&D efforts, which have resulted in the introduction of novel drug-delivery systems. The advancements in drug-delivery systems increase the adoption of novel drugs to treat central nervous system diseases. The increasing incidences of central nervous system disorders such as Alzheimer’s disease, epilepsy, Parkinson’s disease, multiple sclerosis, and stroke and the rising demand for effective drugs are raising the usage of CNS drugs. However, the requirement of high capital investment and adequate infrastructure for drug discovery and development, and stringent regulations for drug approvals are significantly impeding the adoption of CNS drugs. In addition, ongoing drug evolution and adoption of AI and ML in CNS drug discovery are increasing the utilization of CNS drugs.Regional InsightsIn the United States, pharmaceutical companies run awareness campaigns about diagnosing and treating CNS diseases and developing new drugs to increase the CNS drug rate. In May 2022, Minoryx Therapeutics, a Barcelona, Spain-based Phase 3 stage biotech company, focused on developing treatments for orphan central nervous system (CNS) disorders. In North America, the rising prevalence of neurological disorders, better reimbursement policies for treating CNS diseases, and increasing investments by companies to develop novel therapeutics have grown the utilization of CNS drugs. Rising approval of generic products owing to the patent expiration of key products, such as Copaxone and Invega, has increased the CNS treatment rate, especially in Asia-Pacifc. In Europe, the rising government investments in improving the healthcare infrastructure and the presence of huge numbers of patients with unfulfilled medical needs raised the usage of CNS drugs.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Central Nervous System Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Central Nervous System Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Central Nervous System Drugs Market, highlighting leading vendors and their innovative profiles. These include A. N. Pharmacia Laboratories Pvt. Ltd., AbbVie Inc., Alkermes PLC, Apotex Inc., Arvelle Therapeutics International GmbH by Angelini Pharma Inc., AstraZeneca PLC, Aurobindo Pharma, BIAL - PORTELA & CA, S.A., Biogen Inc., Catalent, Inc., CNS Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Divi's Laboratories Ltd., Dr. Reddy's Laboratories Ltd., East India Pharmaceutical Works Ltd., Eisai Co., Ltd., Eli Lilly and Company, Endo International PLC by DuPont de Nemours, Inc., Eridanus Healthcare, EVERSANA, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, H. Lundbeck A/S, Intas Pharmaceuticals Ltd., Jabs Biotech Pvt. Ltd., Johnson & Johnson Services, Inc., La Renon Healthcare Pvt. Ltd., Lupin Ltd., Merck & Co., Micro Labs Ltd., Midas Pharma GmbH, Neuracle Lifesciences Private Limited, Neurocon Inc., Novartis Group, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Priavoid GmbH, Reliance Formulations Pvt. Ltd., Sanofi S.A., Servier Laboratories (Aust) Pty Ltd, Shine Pharmaceuticals Ltd., Somacare, SteriMax Inc., Sun Pharmaceuticals Pvt Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., UCB S.A., Wellona Pharma, and Zee Laboratories Limited.

Market Segmentation & Coverage


This research report categorizes the Central Nervous System Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Classes
Analgesics
Anesthetics
Anti-Epileptics
Anti-Parkinson Drugs
Antidepressant
Diseases
CNS Trauma
Infectious Diseases
Mental Health
Neurodegenerative Diseases
Neurovascular Diseases
Drug Type
Biologics
Non-Biologics
Distribution Channel
Hospital Pharmacies
Online
Retail Pharmacies
Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas
Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam
Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Central Nervous System Drugs Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Central Nervous System Drugs Market?
3. What are the technology trends and regulatory frameworks in the Central Nervous System Drugs Market?
4. What is the market share of the leading vendors in the Central Nervous System Drugs Market?
5. Which modes and strategic moves are suitable for entering the Central Nervous System Drugs Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Central Nervous System Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing incidence of neurological and cognitive disorders across the globe
5.1.1.2. Ascending government programs and awareness activities to spread the knowledge about neurological risk factors and symptoms
5.1.1.3. Rise in geriatric population with neurological complications
5.1.2. Restraints
5.1.2.1. Requirement of high capital investment and adequate infrastructure for drug discovery and development
5.1.3. Opportunities
5.1.3.1. Ongoing drug evolvement to meet the unique and changing demands of psychiatry and neurology field
5.1.3.2. Adoption of artificial intelligence and machine learning in CNS drug discovery
5.1.4. Challenges
5.1.4.1. Stringent regulations for product approvals and concern regarding product recalls
5.1.4.2. Dearth of subject expertise in the neurological field amid the competent studies
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Central Nervous System Drugs Market, by Drug Classes
6.1. Introduction
6.2. Analgesics
6.3. Anesthetics
6.4. Anti-Epileptics
6.5. Anti-Parkinson Drugs
6.6. Antidepressant
7. Central Nervous System Drugs Market, by Diseases
7.1. Introduction
7.2. CNS Trauma
7.3. Infectious Diseases
7.4. Mental Health
7.5. Neurodegenerative Diseases
7.6. Neurovascular Diseases
8. Central Nervous System Drugs Market, by Drug Type
8.1. Introduction
8.2. Biologics
8.3. Non-Biologics
9. Central Nervous System Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online
9.4. Retail Pharmacies
10. Americas Central Nervous System Drugs Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Central Nervous System Drugs Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Central Nervous System Drugs Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
13.3.1. Merger & Acquisition
13.3.1.1. Neuraxpharm announces closing of acquisition of established products from Sanofi
13.3.1.2. Intrinsic Medicine enters merger deal with Phoenix Biotech
13.3.1.3. Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement
13.3.1.4. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
13.3.2. Agreement, Collaboration, & Partnership
13.3.2.1. Astex and Cardiff University announce drug discovery collaboration
13.3.2.2. PrecisionLife and Ono sign multi-target partnership for CNS disorders
13.3.2.3. Collaboration will focus on therapy targets for CNS disorders
13.3.2.4. Gensaic enters into collaboration to develop
13.3.2.5. IAMA Therapeutics Partners with the Italian Institute of Technology to Embark on Landmark Research on Neuroscience Drug Discovery
13.3.2.6. AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. A. N. Pharmacia Laboratories Pvt. Ltd.
14.1.2. AbbVie Inc.
14.1.3. Alkermes PLC
14.1.4. Apotex Inc.
14.1.5. Arvelle Therapeutics International GmbH by Angelini Pharma Inc.
14.1.6. AstraZeneca PLC
14.1.7. Aurobindo Pharma
14.1.8. BIAL - PORTELA & CA, S.A.
14.1.9. Biogen Inc.
14.1.10. Catalent, Inc.
14.1.11. CNS Pharmaceuticals, Inc.
14.1.12. Daiichi Sankyo Company, Limited
14.1.13. Divi's Laboratories Ltd.
14.1.14. Dr. Reddy's Laboratories Ltd.
14.1.15. East India Pharmaceutical Works Ltd.
14.1.16. Eisai Co., Ltd.
14.1.17. Eli Lilly and Company
14.1.18. Endo International PLC by DuPont de Nemours, Inc.
14.1.19. Eridanus Healthcare
14.1.20. EVERSANA
14.1.21. F. Hoffmann-La Roche AG
14.1.22. GlaxoSmithKline PLC
14.1.23. H. Lundbeck A/S
14.1.24. Intas Pharmaceuticals Ltd.
14.1.25. Jabs Biotech Pvt. Ltd.
14.1.26. Johnson & Johnson Services, Inc.
14.1.27. La Renon Healthcare Pvt. Ltd.
14.1.28. Lupin Ltd.
14.1.29. Merck & Co.
14.1.30. Micro Labs Ltd.
14.1.31. Midas Pharma GmbH
14.1.32. Neuracle Lifesciences Private Limited
14.1.33. Neurocon Inc.
14.1.34. Novartis Group
14.1.35. Otsuka Pharmaceutical Co., Ltd.
14.1.36. Pfizer Inc.
14.1.37. Priavoid GmbH
14.1.38. Reliance Formulations Pvt. Ltd.
14.1.39. Sanofi S.A.
14.1.40. Servier Laboratories (Aust) Pty Ltd
14.1.41. Shine Pharmaceuticals Ltd.
14.1.42. Somacare
14.1.43. SteriMax Inc.
14.1.44. Sun Pharmaceuticals Pvt Ltd.
14.1.45. Takeda Pharmaceutical Co. Ltd.
14.1.46. Teva Pharmaceutical Industries Ltd.
14.1.47. Torrent Pharmaceuticals Ltd.
14.1.48. UCB S.A.
14.1.49. Wellona Pharma
14.1.50. Zee Laboratories Limited
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
FIGURE 1. CENTRAL NERVOUS SYSTEM DRUGS MARKET RESEARCH PROCESS
FIGURE 2. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CENTRAL NERVOUS SYSTEM DRUGS MARKET DYNAMICS
FIGURE 7. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2023 VS 2030 (%)
FIGURE 8. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2023 VS 2030 (%)
FIGURE 10. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 12. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 14. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. CENTRAL NERVOUS SYSTEM DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. CENTRAL NERVOUS SYSTEM DRUGS MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings